View ValuationNabriva Therapeutics 将来の成長Future 基準チェック /06現在、 Nabriva Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • May 12Consensus revenue estimates fall by 10%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$43.9m to US$39.3m. Forecast losses increased from -US$0.67 to -US$0.73 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 28% to US$0.21 over the past week.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.Major Estimate Revision • Apr 05Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$52.8m to US$43.9m. Forecast losses increased from -US$0.62 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 11% to US$0.42 over the past week.Breakeven Date Change • Mar 31No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 3 analysts covering Nabriva Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.6m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Major Estimate Revision • Aug 12Consensus revenue estimates increase to US$29.6mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.2m to US$29.6m. Forecast losses expected to reduce from -US$1.29 to -US$1.11 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$3.68 to US$2.68. Share price fell 7.4% to US$1.12 over the past week.すべての更新を表示Recent updatesお知らせ • Oct 26Nabriva Therapeutics plc Files Form 15Nabriva Therapeutics plc has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Ordinary Shares under the Securities Exchange Act of 1934, as amended. The par value of the company's Ordinary Shares, nominal value $0.01 per share.お知らせ • Sep 08Nasdaq to Delist the Ordinary Shares of Nabriva TherapeuticsOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the ordinary shares of Nabriva Therapeutics plc. Nabriva Therapeutics plc’s securities were suspended on August 1, 2023, and have not traded on Nasdaq since that time.お知らせ • Aug 02+ 1 more updateNabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite IndexNabriva Therapeutics plc has been dropped from Nasdaq Composite Index.お知らせ • Jul 25Nabriva Therapeutics Receives A Delisting Determination Letter from NasdaqOn July 21, 2023, Nabriva Therapeutics plc (the Company") received a delisting determination letter (the Determination Letter") from The Nasdaq Stock Market LLC (Nasdaq"). The Determination Letter indicated that, based on (i) the Company's continued non-compliance with the Nasdaq Capital Market's requirement to have a minimum stockholders' equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the Rule") and (ii) the Company's confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company's ordinary shares, nominal value $0.01 per share (the Ordinary Shares"), will be suspended from trading on Nasdaq at the open of business on August 1, 2023, unless the Company requests an appeal of this determination. The Determination Letter also indicated that unless the Company requests an appeal of Nasdaq's determination, Nasdaq intends to file a Form 25-NSE with the Securities and Exchange Commission in order to effect the formal delisting of the Company's Ordinary Shares from Nasdaq. The Company does not plan to appeal Nasdaq's determination. As previously disclosed, the Company was initially notified by Nasdaq on May 25, 2023 that the Company was not in compliance with the Rule because the stockholders' equity (deficit) of the Company of $(4,357,000) as of March 31, 2023, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, was below the minimum stockholders' equity requirement of $2,500,000. The Ordinary Shares may be eligible to be quoted on the Pink Open Market operated by the OTC Markets Group Inc. if a market maker sponsors the security and complies with Rule 15c2-11 under the Securities Exchange Act of 1934, as amended, but the Company can provide no assurances that a public market for trading the Ordinary Shares will exist after the expected suspension of trading on August 1, 2023.お知らせ • Jul 10+ 1 more updateNabriva Therapeutics plc Appoints Dave Maggio as Chief Financial OfficerOn June 30, 2023, the Board of Directors of Nabriva Therapeutics plc appointed Dave Maggio, a representative of Armanino LLP (“Armanino”), as Chief Financial Officer of the Company, effective immediately. Mr. Maggio will provide services as an executive officer of the Company pursuant to a consulting agreement to which the Company is a party with Armanino. Mr. Maggio, age 64, has served as a Director at Armanino in the firm’s Corporate Finance and Restructuring practice since November 2021. Mr. Maggio co-founded and has also operated Omni Professional Services, LLC since January 2021 and has served as an Operating Partner at CornerPost Capital Partners, LLC, since January 2010. Mr. Maggio received a B.S. in Accounting from Louisiana State University and completed the Northwestern/Kellogg Business School Executive Merger & Acquisitions Program.お知らせ • May 16Nabriva Therapeutics plc announced delayed 10-Q filingOn 05/15/2023, Nabriva Therapeutics plc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 21Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive OfficerOn January 15, 2023, in connection with the separation of employment of Mr. Schroeder, the Board of Directors appointed J. Christopher Naftzger as Interim Chief Executive Officer, effective immediately. J. Christopher Naftzger, age 56, has served as the Company’s general counsel and secretary since September 1, 2021. Previously, Mr. Naftzger served as General Counsel and Corporate Secretary of Krystal Biotech, an emerging-stage, gene therapy company, from February 2020 to May 2021. Before joining Krystal, he was Vice President, Deputy General Counsel and Assistant Secretary of Nabriva Therapeutics from January 2017 to January 2020. Prior to Nabriva, Mr. Naftzger served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Medical Solutions, a developer and manufacturer of innovative drug delivery systems. Mr. Naftzger also held senior in-house counsel positions with Chesapeake Corporation and Koch Industries, and was a corporate partner with Blank Rome LLP in Washington, DC. Mr. Naftzger obtained his undergraduate degree from Hampden-Sydney College and his law degree from the Willamette University College of Law.Seeking Alpha • Sep 15Nabriva Therapeutics to effect 1-for-25 reverse stock splitBiopharmaceutical company Nabriva Therapeutics (NASDAQ:NBRV) is set to effect a 1-for-25 reverse stock split, effective for trading purposes on the Nasdaq Capital Market as of Sep. 16. The company's shareholders approved the stock split at the annual general meeting of the shareholders on Aug. 11. The split is still subject to and conditional upon the board determining that the action is necessary for compliance with the minimum $1.00 per share requirement of Nasdaq. The shares will continue to trade on the stock exchange under the symbol NBRV. The reverse stock split will reduce the number of outstanding ordinary shares to ~2.8M from ~69.7M and reduce the number of authorized ordinary shares to 12M from 300M. NBRV shares were trading +63.24% pre-market. Source: Press ReleaseSeeking Alpha • Jul 18Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug XenletaNabriva Therapeutics (NASDAQ:NBRV) signed a distribution agreement with Er-Kim for the oral and intravenous formulations of its medicine Xenleta (lefamulin). Xenleta is used to treat adults with community-acquired bacterial pneumonia. Under the agreement, Er-Kim gains exclusive rights to distribute Xenleta in Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. Ireland-based Nabriva said Er-Kim also may distribute the drug to an additional five countries through a Named Patient Usage (NPU) program. Nabriva noted that it will be the exclusive supplier of the therapy to Er-Kim. NBRV +19.12% to $0.23 premarket July 18Major Estimate Revision • May 12Consensus revenue estimates fall by 10%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$43.9m to US$39.3m. Forecast losses increased from -US$0.67 to -US$0.73 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 28% to US$0.21 over the past week.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (up from US$0.53 loss in 1Q 2021). Revenue: US$8.02m (up 217% from 1Q 2021). Net loss: US$11.8m (loss narrowed 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 48%, compared to a 7.6% growth forecast for the industry in the US.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.Major Estimate Revision • Apr 05Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$52.8m to US$43.9m. Forecast losses increased from -US$0.62 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 11% to US$0.42 over the past week.分析記事 • Apr 04Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022One thing we could say about the analysts on Nabriva Therapeutics plc ( NASDAQ:NBRV ) - they aren't optimistic, having...Breakeven Date Change • Mar 31No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 3 analysts covering Nabriva Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.6m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Jan 01CEO & Director recently bought US$57k worth of stockOn the 28th of December, Theodore Schroeder bought around 100k shares on-market at roughly US$0.57 per share. This was the largest purchase by an insider in the last 3 months. Theodore has been a buyer over the last 12 months, purchasing a net total of US$114k worth in shares.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$8.86m (up US$7.57m from 3Q 2020). Net loss: US$10.7m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 17CEO & Director recently bought US$57k worth of stockOn the 14th of September, Theodore Schroeder bought around 50k shares on-market at roughly US$1.13 per share. This was the largest purchase by an insider in the last 3 months. This was Theodore's only on-market trade for the last 12 months.Major Estimate Revision • Aug 12Consensus revenue estimates increase to US$29.6mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.2m to US$29.6m. Forecast losses expected to reduce from -US$1.29 to -US$1.11 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$3.68 to US$2.68. Share price fell 7.4% to US$1.12 over the past week.分析記事 • Aug 11Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) ForecastsShareholders in Nabriva Therapeutics plc ( NASDAQ:NBRV ) may be thrilled to learn that the analysts have just delivered...Reported Earnings • Aug 09Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$8.24m (up US$7.76m from 2Q 2020). Net loss: US$11.8m (loss narrowed 24% from 2Q 2020).Executive Departure • Aug 04Independent Director George Talbot has left the companyOn the 28th of July, George Talbot's tenure as Independent Director ended after 4.1 years in the role. As of March 2021, George still personally held only 4.76k shares (US$7.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 3.08 years.Board Change • Aug 04Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Stephen Webster was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Jul 22We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO CompensationThe underwhelming share price performance of Nabriva Therapeutics plc ( NASDAQ:NBRV ) in the past three years would...Breakeven Date Change • Jul 13No longer forecast to breakevenThe 4 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$16.5m in 2023. New consensus forecast suggests the company will make a loss of US$4.63m in 2023.Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$29.9m to US$29.3m. 2021 losses expected to reduce from -US$1.67 to -US$1.48 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price rose 2.7% to US$1.51 over the past week.Major Estimate Revision • May 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$30.8m to US$29.9m. 2021 losses expected to reduce from -US$1.95 to -US$1.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 14% to US$1.37 over the past week.Reported Earnings • May 09First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$2.53m (up 221% from 1Q 2020). Net loss: US$14.0m (loss narrowed 40% from 1Q 2020).Major Estimate Revision • Apr 17Consensus revenue estimates increase to US$30.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$22.9m to US$30.8m. Forecast losses expected to reduce from -US$2.03 to -US$1.95 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 9.6% to US$1.50 over the past week.Major Estimate Revision • Mar 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$15.3m to US$22.9m. EPS estimate unchanged from -US$2.03 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target down from US$9.00 to US$6.00. Share price rose 17% to US$2.05 over the past week.Executive Departure • Mar 15Chief Financial Officer has left the companyOn the 12th of March, Gary Sender's tenure as Chief Financial Officer ended after 3.9 years in the role. As of December 2020, Gary personally held only 20.54k shares (US$50k worth at the time). Gary is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 13Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$5.03m (down 47% from FY 2019). Net loss: US$69.5m (loss narrowed 16% from FY 2019). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 69% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Mar 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 87%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US.Is New 90 Day High Low • Mar 02New 90-day low: US$1.92The company is down 56% from its price of US$4.40 on 01 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.分析記事 • Feb 16When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?We feel now is a pretty good time to analyse Nabriva Therapeutics plc's ( NASDAQ:NBRV ) business as it appears the...Is New 90 Day High Low • Dec 10New 90-day low: US$3.40The company is down 42% from its price of US$5.83 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.09 loss per shareThird quarter 2020 results: Net loss: US$13.0m (loss narrowed 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 08Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 187%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 423%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.Major Estimate Revision • Nov 03Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$5.58m to US$3.58m. Earning per share (EPS) estimate was unchanged from the last update at -US$0.48. The Pharmaceuticals industry in the US is expected to see an average net income growth of 6.7% next year. The consensus price target of US$1.75 was unchanged from the last update. Share price is down by 8.3% to US$0.49 over the past week.Is New 90 Day High Low • Oct 29New 90-day low: US$0.51The company is down 33% from its price of US$0.76 on 31 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 25New 90-day low: US$0.53The company is down 24% from its price of US$0.70 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nabriva Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NBRV.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202330-55-13-13N/A3/31/202337-54-27-26N/A12/31/202237-57-37-37N/A9/30/202236-47-41-41N/A6/30/202235-47-48-48N/A3/31/202234-47-54-54N/A12/31/202129-49-60-60N/A9/30/202122-54-67-67N/A6/30/202115-57-66-66N/A3/31/20217-60-65-65N/A12/31/20205-69-71-71N/A9/30/20203-75-74-73N/A6/30/20209-80-76-76N/A3/31/20209-86-79-79N/A12/31/20199-83-72-72N/A9/30/201910-91-79-79N/A6/30/20193-126-81-81N/A3/31/20194-122-77-77N/A12/31/201810-115-73-73N/A9/30/201810-106-75-75N/A6/30/201811-76-74-72N/A3/31/201811-72-72-71N/A12/31/20175-74-71-69N/A9/30/20177-67-57-56N/A6/30/20176-59-54-53N/A3/31/20177-57N/A-52N/A12/31/20166-55N/A-48N/A9/30/20165-67N/A-41N/A6/30/20165-61N/AN/AN/A3/31/20165-55N/A-30N/A12/31/20154-51N/A-22N/A9/30/20153-30N/A-21N/A6/30/20152-26N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NBRV.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NBRV.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NBRV.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NBRV.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NBRV.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NBRV.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 06:09終値2026/05/18 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nabriva Therapeutics plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Jason Matthew GerberryBofA Global ResearchChiara RussoCantor Fitzgerald & Co.Antonio ArceH.C. Wainwright & Co.7 その他のアナリストを表示
Major Estimate Revision • May 12Consensus revenue estimates fall by 10%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$43.9m to US$39.3m. Forecast losses increased from -US$0.67 to -US$0.73 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 28% to US$0.21 over the past week.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.
Major Estimate Revision • Apr 05Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$52.8m to US$43.9m. Forecast losses increased from -US$0.62 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 11% to US$0.42 over the past week.
Breakeven Date Change • Mar 31No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.
Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 3 analysts covering Nabriva Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.6m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Major Estimate Revision • Aug 12Consensus revenue estimates increase to US$29.6mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.2m to US$29.6m. Forecast losses expected to reduce from -US$1.29 to -US$1.11 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$3.68 to US$2.68. Share price fell 7.4% to US$1.12 over the past week.
お知らせ • Oct 26Nabriva Therapeutics plc Files Form 15Nabriva Therapeutics plc has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Ordinary Shares under the Securities Exchange Act of 1934, as amended. The par value of the company's Ordinary Shares, nominal value $0.01 per share.
お知らせ • Sep 08Nasdaq to Delist the Ordinary Shares of Nabriva TherapeuticsOn September 7, 2023, The Nasdaq Stock Market announced that it will delist the ordinary shares of Nabriva Therapeutics plc. Nabriva Therapeutics plc’s securities were suspended on August 1, 2023, and have not traded on Nasdaq since that time.
お知らせ • Aug 02+ 1 more updateNabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite IndexNabriva Therapeutics plc has been dropped from Nasdaq Composite Index.
お知らせ • Jul 25Nabriva Therapeutics Receives A Delisting Determination Letter from NasdaqOn July 21, 2023, Nabriva Therapeutics plc (the Company") received a delisting determination letter (the Determination Letter") from The Nasdaq Stock Market LLC (Nasdaq"). The Determination Letter indicated that, based on (i) the Company's continued non-compliance with the Nasdaq Capital Market's requirement to have a minimum stockholders' equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the Rule") and (ii) the Company's confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company's ordinary shares, nominal value $0.01 per share (the Ordinary Shares"), will be suspended from trading on Nasdaq at the open of business on August 1, 2023, unless the Company requests an appeal of this determination. The Determination Letter also indicated that unless the Company requests an appeal of Nasdaq's determination, Nasdaq intends to file a Form 25-NSE with the Securities and Exchange Commission in order to effect the formal delisting of the Company's Ordinary Shares from Nasdaq. The Company does not plan to appeal Nasdaq's determination. As previously disclosed, the Company was initially notified by Nasdaq on May 25, 2023 that the Company was not in compliance with the Rule because the stockholders' equity (deficit) of the Company of $(4,357,000) as of March 31, 2023, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, was below the minimum stockholders' equity requirement of $2,500,000. The Ordinary Shares may be eligible to be quoted on the Pink Open Market operated by the OTC Markets Group Inc. if a market maker sponsors the security and complies with Rule 15c2-11 under the Securities Exchange Act of 1934, as amended, but the Company can provide no assurances that a public market for trading the Ordinary Shares will exist after the expected suspension of trading on August 1, 2023.
お知らせ • Jul 10+ 1 more updateNabriva Therapeutics plc Appoints Dave Maggio as Chief Financial OfficerOn June 30, 2023, the Board of Directors of Nabriva Therapeutics plc appointed Dave Maggio, a representative of Armanino LLP (“Armanino”), as Chief Financial Officer of the Company, effective immediately. Mr. Maggio will provide services as an executive officer of the Company pursuant to a consulting agreement to which the Company is a party with Armanino. Mr. Maggio, age 64, has served as a Director at Armanino in the firm’s Corporate Finance and Restructuring practice since November 2021. Mr. Maggio co-founded and has also operated Omni Professional Services, LLC since January 2021 and has served as an Operating Partner at CornerPost Capital Partners, LLC, since January 2010. Mr. Maggio received a B.S. in Accounting from Louisiana State University and completed the Northwestern/Kellogg Business School Executive Merger & Acquisitions Program.
お知らせ • May 16Nabriva Therapeutics plc announced delayed 10-Q filingOn 05/15/2023, Nabriva Therapeutics plc announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 21Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive OfficerOn January 15, 2023, in connection with the separation of employment of Mr. Schroeder, the Board of Directors appointed J. Christopher Naftzger as Interim Chief Executive Officer, effective immediately. J. Christopher Naftzger, age 56, has served as the Company’s general counsel and secretary since September 1, 2021. Previously, Mr. Naftzger served as General Counsel and Corporate Secretary of Krystal Biotech, an emerging-stage, gene therapy company, from February 2020 to May 2021. Before joining Krystal, he was Vice President, Deputy General Counsel and Assistant Secretary of Nabriva Therapeutics from January 2017 to January 2020. Prior to Nabriva, Mr. Naftzger served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Medical Solutions, a developer and manufacturer of innovative drug delivery systems. Mr. Naftzger also held senior in-house counsel positions with Chesapeake Corporation and Koch Industries, and was a corporate partner with Blank Rome LLP in Washington, DC. Mr. Naftzger obtained his undergraduate degree from Hampden-Sydney College and his law degree from the Willamette University College of Law.
Seeking Alpha • Sep 15Nabriva Therapeutics to effect 1-for-25 reverse stock splitBiopharmaceutical company Nabriva Therapeutics (NASDAQ:NBRV) is set to effect a 1-for-25 reverse stock split, effective for trading purposes on the Nasdaq Capital Market as of Sep. 16. The company's shareholders approved the stock split at the annual general meeting of the shareholders on Aug. 11. The split is still subject to and conditional upon the board determining that the action is necessary for compliance with the minimum $1.00 per share requirement of Nasdaq. The shares will continue to trade on the stock exchange under the symbol NBRV. The reverse stock split will reduce the number of outstanding ordinary shares to ~2.8M from ~69.7M and reduce the number of authorized ordinary shares to 12M from 300M. NBRV shares were trading +63.24% pre-market. Source: Press Release
Seeking Alpha • Jul 18Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug XenletaNabriva Therapeutics (NASDAQ:NBRV) signed a distribution agreement with Er-Kim for the oral and intravenous formulations of its medicine Xenleta (lefamulin). Xenleta is used to treat adults with community-acquired bacterial pneumonia. Under the agreement, Er-Kim gains exclusive rights to distribute Xenleta in Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. Ireland-based Nabriva said Er-Kim also may distribute the drug to an additional five countries through a Named Patient Usage (NPU) program. Nabriva noted that it will be the exclusive supplier of the therapy to Er-Kim. NBRV +19.12% to $0.23 premarket July 18
Major Estimate Revision • May 12Consensus revenue estimates fall by 10%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$43.9m to US$39.3m. Forecast losses increased from -US$0.67 to -US$0.73 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$2.00 unchanged from last update. Share price fell 28% to US$0.21 over the past week.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (up from US$0.53 loss in 1Q 2021). Revenue: US$8.02m (up 217% from 1Q 2021). Net loss: US$11.8m (loss narrowed 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 48%, compared to a 7.6% growth forecast for the industry in the US.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.
Major Estimate Revision • Apr 05Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$52.8m to US$43.9m. Forecast losses increased from -US$0.62 to -US$0.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 11% to US$0.42 over the past week.
分析記事 • Apr 04Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022One thing we could say about the analysts on Nabriva Therapeutics plc ( NASDAQ:NBRV ) - they aren't optimistic, having...
Breakeven Date Change • Mar 31No longer forecast to breakevenThe 2 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$15.0m in 2024. New consensus forecast suggests the company will make a loss of US$560.0k in 2024.
Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 3 analysts covering Nabriva Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$10.6m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jan 01CEO & Director recently bought US$57k worth of stockOn the 28th of December, Theodore Schroeder bought around 100k shares on-market at roughly US$0.57 per share. This was the largest purchase by an insider in the last 3 months. Theodore has been a buyer over the last 12 months, purchasing a net total of US$114k worth in shares.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$8.86m (up US$7.57m from 3Q 2020). Net loss: US$10.7m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 17CEO & Director recently bought US$57k worth of stockOn the 14th of September, Theodore Schroeder bought around 50k shares on-market at roughly US$1.13 per share. This was the largest purchase by an insider in the last 3 months. This was Theodore's only on-market trade for the last 12 months.
Major Estimate Revision • Aug 12Consensus revenue estimates increase to US$29.6mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$25.2m to US$29.6m. Forecast losses expected to reduce from -US$1.29 to -US$1.11 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$3.68 to US$2.68. Share price fell 7.4% to US$1.12 over the past week.
分析記事 • Aug 11Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) ForecastsShareholders in Nabriva Therapeutics plc ( NASDAQ:NBRV ) may be thrilled to learn that the analysts have just delivered...
Reported Earnings • Aug 09Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$8.24m (up US$7.76m from 2Q 2020). Net loss: US$11.8m (loss narrowed 24% from 2Q 2020).
Executive Departure • Aug 04Independent Director George Talbot has left the companyOn the 28th of July, George Talbot's tenure as Independent Director ended after 4.1 years in the role. As of March 2021, George still personally held only 4.76k shares (US$7.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 3.08 years.
Board Change • Aug 04Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Stephen Webster was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Jul 22We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO CompensationThe underwhelming share price performance of Nabriva Therapeutics plc ( NASDAQ:NBRV ) in the past three years would...
Breakeven Date Change • Jul 13No longer forecast to breakevenThe 4 analysts covering Nabriva Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$16.5m in 2023. New consensus forecast suggests the company will make a loss of US$4.63m in 2023.
Major Estimate Revision • May 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$29.9m to US$29.3m. 2021 losses expected to reduce from -US$1.67 to -US$1.48 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price rose 2.7% to US$1.51 over the past week.
Major Estimate Revision • May 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$30.8m to US$29.9m. 2021 losses expected to reduce from -US$1.95 to -US$1.67 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 14% to US$1.37 over the past week.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$2.53m (up 221% from 1Q 2020). Net loss: US$14.0m (loss narrowed 40% from 1Q 2020).
Major Estimate Revision • Apr 17Consensus revenue estimates increase to US$30.8mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$22.9m to US$30.8m. Forecast losses expected to reduce from -US$2.03 to -US$1.95 per share. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$6.00 unchanged from last update. Share price fell 9.6% to US$1.50 over the past week.
Major Estimate Revision • Mar 18Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$15.3m to US$22.9m. EPS estimate unchanged from -US$2.03 at last update. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target down from US$9.00 to US$6.00. Share price rose 17% to US$2.05 over the past week.
Executive Departure • Mar 15Chief Financial Officer has left the companyOn the 12th of March, Gary Sender's tenure as Chief Financial Officer ended after 3.9 years in the role. As of December 2020, Gary personally held only 20.54k shares (US$50k worth at the time). Gary is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 13Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$5.03m (down 47% from FY 2019). Net loss: US$69.5m (loss narrowed 16% from FY 2019). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 69% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Mar 13Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 87%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US.
Is New 90 Day High Low • Mar 02New 90-day low: US$1.92The company is down 56% from its price of US$4.40 on 01 December 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
分析記事 • Feb 16When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?We feel now is a pretty good time to analyse Nabriva Therapeutics plc's ( NASDAQ:NBRV ) business as it appears the...
Is New 90 Day High Low • Dec 10New 90-day low: US$3.40The company is down 42% from its price of US$5.83 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.09 loss per shareThird quarter 2020 results: Net loss: US$13.0m (loss narrowed 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 187%. Earnings per share (EPS) also surpassed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 423%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.
Major Estimate Revision • Nov 03Analysts update estimatesThe 2020 consensus revenue estimate was lowered from US$5.58m to US$3.58m. Earning per share (EPS) estimate was unchanged from the last update at -US$0.48. The Pharmaceuticals industry in the US is expected to see an average net income growth of 6.7% next year. The consensus price target of US$1.75 was unchanged from the last update. Share price is down by 8.3% to US$0.49 over the past week.
Is New 90 Day High Low • Oct 29New 90-day low: US$0.51The company is down 33% from its price of US$0.76 on 31 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 25New 90-day low: US$0.53The company is down 24% from its price of US$0.70 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.